Awakn Chief Medical Officer, Dr. Ben Sessa, Announces Results of the World’s First ‘MDMA in Alcohol Use Disorder’ Clinical Trial

London, United Kingdom–(Newsfile Corp. – February 19, 2021) – Awakn Life Sciences Inc. announces today the publication of results from its CMO Dr. Ben Sessa’s Bristol Imperial MDMA in Alcoholism (BIMA) trial, an open-label safety, tolerability and proof-of-concept study investigating the potential role for MDMA-Assisted Psychotherapy in treating patients with alcohol use disorder (AUD).

Source